SCHEMBL12497263

SCHEMBL12497263

CNC(=O)Cn1c(C)nc2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.69
HTT P42858 2/20 0.69
TSHR P16473 1/20 0.69
GSK3B P49841 8/20 0.67
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
CYP2D6 P10635 1/20 0.58
HPGD P15428 1/20 0.58
POLB P06746 1/20 0.57
RAB9A P51151 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ALPL P05186 1/20 0.56
ALPP P05187 1/20 0.56
ALPG P10696 1/20 0.56
PLAA Q9Y263 1/20 0.56
APAF1 O14727 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27858704 0.87 MMP2 (0.73) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL28995203 0.83 LMNA (0.56) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL3587930 0.83 KDM4E (0.69) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL20715449 0.82 KMT2A (0.76) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL3430135 0.82 LMNA (1.00) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL12495433 0.82 ALDH1A1 (0.72) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL5252741 0.81 LMNA (0.60) LMNAHTTTSHRGSK3BRAB9A
SCHEMBL12501224 0.81 HDAC1 (0.56) LMNA
SCHEMBL17824289 0.80 LMNA (0.66) LMNAHTTTSHRGSK3BKMT2A
SCHEMBL11400323 0.80 KDM4E (0.62) LMNAHTTTSHRGSK3BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180000768-A1 INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-01-04 US disclosed
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180000768-A1 INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS GLP1R, GIPR, FXR1 LMNA 2161/4885HTT 4547/4885TSHR 237/4885
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD LMNA 2528/4885HTT 1426/4885TSHR 2169/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD LMNA 2528/4885HTT 1426/4885TSHR 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.